Dose-Response Characteristics for Suppression of Low Molecular Weight Plasma Insulin-Like Growth Factor-Binding Protein by Insulin*
- 1 January 1989
- journal article
- research article
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 68 (1) , 135-140
- https://doi.org/10.1210/jcem-68-1-135
Abstract
We previously demonstrated that supraphysiological insulin concentrations reducedthe plasma 34K insulinlike growth factor-binding protein (IGF-BP) concentrations in humans. Inthis study we examined whether physiological changes in plasma insulin concentrations regulateIGF-BP and, if so, whether the regulation is influenced by race, glucose tolerance, or rate of glucose metabolism. For these purposes we 1) analyzed the relationship between fasting plasma insulin and IGF-BP concentrations in 2 racial groups (23 Caucasians and 35 southwestern American Indians), 2) measured the response of plasma IGF-BP to oral glucose in 20 normal subjects, and 3) determined the dose-response characteristics of plasma IGF-BP to glucose and insulin in23 normal subjects at 4 different insulin and glucose concentrations. The fasting plasma insulin concentration was inversely related to the plasma IGF-BP concentration in both the Caucasian and Indian groups (P < 0.0001). In the Caucasian group the mean plasma IGF-BP concentrationwas higher [15 ± 4 (±se) μg/L] than in the Indian group (8 ± 2 μg/L; P < 0.05). This difference was independent of race and glucose tolerance, and it could be explained by lower plasma insulin concentrations in the Caucasian (387 ± 50 pmol/L) than in the Indian group (215 ± 43 pmol/L; P < 0.001). After oralglucose administration, the insulin concentration (423 ± 72 pmol/L) was maximal 30 min after glucose treatment, and significant suppression of the IGF-BP concentration occurred at 90 min. Analysis of the dose-response curves revealed maximal suppression of IGF-BP at about 1150 pmol/L insulin, and halfmaximal suppression at about 290 pmol/L. The plasma glucose concentration or the rate of glucose metabolism had no effect on the IGF-BP concentration. These data suggest that insulin is a major regulator of plasma IGF-BP concentrations under physiological conditions.Keywords
This publication has 22 references indexed in Scilit:
- Placental Protein 12 Is a Decidual Protein that Binds Somatomedin and Has an Identical N-Terminal Amino Acid Sequence with Sdmatomedin-Binding Protein from Human Amhiotic Fluid*Endocrinology, 1986
- The somatomedin-binding protein isolated from a human hepatoma cell line is identical to the human amniotic fluid somatomedin-binding proteinBiochemical and Biophysical Research Communications, 1985
- Affinity-labeled plasma somatomedin-C/insulinlike growth factor I binding proteins. Evidence of growth hormone dependence and subunit structure.Journal of Clinical Investigation, 1985
- Isolation of a Somatomedin-Binding Protein from Preterm Amniotic Fluid. Development of a Radioimmunoassay*Journal of Clinical Endocrinology & Metabolism, 1984
- Placental protein 12 (PP12): Factors affecting levels in late pregnancyPlacenta, 1984
- Liberation of Immunoreactive Somatomedin-C from Its Binding Proteins by Proteolytic Enzymes and Heparin*Journal of Clinical Endocrinology & Metabolism, 1983
- Pitfalls in the Somatomedin-C Radioimmunoassay1Journal of Clinical Endocrinology & Metabolism, 1982
- Isolierung und Charakterisierung eines neuen plazentaspezifischen Proteins (PP12)Archiv für Gynäkologie, 1980
- Glucose clamp technique: a method for quantifying insulin secretion and resistance.American Journal of Physiology-Endocrinology and Metabolism, 1979
- Coated Charcoal Immunoassay of InsulinJournal of Clinical Endocrinology & Metabolism, 1965